Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.
Montemagno C, Dumas L, Cavaillès P, Ahmadi M, Bacot S, Debiossat M, Soubies A, Djaïleb L, Leenhardt J, Leiris N, Dufies M, Pagès G, Hernot S, Devoogdt N, Perret P, Riou L, Fagret D, Ghezzi C, Broisat A. Montemagno C, et al. Among authors: pages g. Cancers (Basel). 2019 Jul 23;11(7):1039. doi: 10.3390/cancers11071039. Cancers (Basel). 2019. PMID: 31340603 Free PMC article.
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G. Dufies M, et al. Among authors: pages g. Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018. Theranostics. 2018. PMID: 29721091 Free PMC article. Clinical Trial.
VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.
Ndiaye PD, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G. Ndiaye PD, et al. Among authors: pages g. Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019. Theranostics. 2019. PMID: 30809300 Free PMC article.
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G. Giuliano S, et al. Among authors: pages g. Theranostics. 2019 Jan 30;9(4):1181-1199. doi: 10.7150/thno.29093. eCollection 2019. Theranostics. 2019. PMID: 30867824 Free PMC article.
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G. Dufies M, et al. Among authors: pages g. Theranostics. 2019 Jul 9;9(18):5332-5346. doi: 10.7150/thno.34681. eCollection 2019. Theranostics. 2019. PMID: 31410218 Free PMC article.
269 results